What are the indications, dosing regimen, contraindications, and monitoring recommendations for Jornay PM (mixed‑amphetamine) when used to treat ADHD?

Jornay PM for ADHD: Clinical Overview

Jornay PM (methylphenidate hydrochloride extended-release) is FDA-approved for treating ADHD in patients 6 years and older, taken once daily in the evening (between 6:30-9:30 PM) to provide symptom control the following morning and throughout the day. 1

Indications

Jornay PM is indicated specifically for ADHD treatment in patients ≥6 years of age. The medication is NOT recommended for children younger than 6 years due to higher plasma exposure and increased adverse reactions (particularly weight loss) compared to older patients at equivalent doses. 1

This aligns with broader guideline recommendations that methylphenidate formulations represent first-line pharmacologic treatment for ADHD in school-aged children, though Jornay PM's unique evening dosing distinguishes it from traditional methylphenidate products 2.

Dosing Regimen

Starting Dose and Titration

• Initial dose: 20 mg once daily in the evening 1
• Timing: Administer between 6:30 PM and 9:30 PM to optimize next-morning onset and all-day efficacy 1
• Titration: Increase weekly by 20 mg increments as needed 1
• Maximum dose: 100 mg daily 1

Administration Details

• Take consistently either with food or without food (choose one approach and maintain it) 1
• Capsules may be swallowed whole OR opened and sprinkled onto applesauce 1
• Critical: Do NOT substitute Jornay PM for other methylphenidate products on a mg-per-mg basis due to its unique delayed-release/extended-release pharmacokinetic profile 1

The evening dosing strategy is unique among ADHD stimulants and addresses the common clinical challenge of early-morning symptom control without requiring morning medication administration.

Contraindications

Absolute Contraindications

• Known hypersensitivity to methylphenidate or any product components 1
• Concurrent MAOI use or use within preceding 14 days 1

Relative Contraindications (Avoid Use)

• Known structural cardiac abnormalities 1
• Cardiomyopathy 1
• Serious cardiac arrhythmias 1
• Coronary artery disease 1
• Other serious cardiac disease 1

Warnings and Precautions

Black Box Warning: Abuse, Misuse, and Addiction

Jornay PM carries high potential for abuse and misuse leading to substance use disorder, including addiction. Misuse and abuse can result in overdose and death. 1 Before prescribing:

• Assess each patient's risk for abuse, misuse, and addiction
• Educate patients and families about these risks
• Counsel on proper storage and disposal
• Throughout treatment, reassess risk and monitor for signs of abuse

Cardiovascular Monitoring

• Monitor blood pressure and pulse regularly 1
• Screen for cardiac disease before initiating treatment
• Consider ECG if cardiac concerns exist

Psychiatric Adverse Reactions

• Screen for risk factors for manic episodes before initiating treatment 1
• Monitor for emergence of psychotic or manic symptoms
• If new psychotic/manic symptoms occur, consider discontinuation 1

Growth Suppression in Pediatric Patients

Closely monitor height and weight in pediatric patients throughout treatment. 1 This is particularly important given that methylphenidate has been associated with growth delays in the first 1-2 years of treatment, though growth typically returns to expected trajectories after 2-3 years 2. Patients not growing or gaining weight as expected may need treatment interruption 1.

Additional Monitoring Requirements

Priapism: Patients should seek immediate medical attention for abnormally sustained or frequent painful erections 1

Peripheral Vasculopathy (including Raynaud's Phenomenon): Careful observation for digital changes is necessary; consider rheumatology referral if signs/symptoms develop 1

Ophthalmologic Concerns:

• Patients at risk for acute angle closure glaucoma (e.g., significant hyperopia) should undergo ophthalmologic evaluation 1
• For patients with open-angle glaucoma or elevated intraocular pressure, prescribe only if benefits outweigh risks and monitor closely 1

Tics and Tourette's Syndrome:

• Assess family history and clinically evaluate for tics/Tourette's before initiating 1
• Monitor regularly for emergence or worsening
• Discontinue if clinically appropriate 1

Common Adverse Reactions

Based on accumulated methylphenidate data, the most common adverse reactions (≥5% and twice placebo rate) include 1:

In all patients:

• Decreased appetite
• Insomnia
• Nausea, vomiting, dyspepsia, abdominal pain
• Weight decrease
• Anxiety, irritability, affect lability
• Dizziness
• Tachycardia
• Blood pressure increase

Additional reactions in pediatric patients (6-12 years):

• Headache
• Psychomotor hyperactivity
• Mood swings

Drug Interactions

Antihypertensive medications: Monitor blood pressure closely and adjust antihypertensive dosing as needed 1

Clinical Context and Positioning

While general ADHD guidelines recommend stimulants as first-line treatment 2, 3, Jornay PM's evening dosing represents a unique approach within the methylphenidate class. Traditional stimulant formulations require morning administration, which can be problematic for early-morning symptom control and medication adherence. The delayed-release/extended-release formulation provides coverage from morning awakening through the day following evening administration.

Key clinical pitfall: Do not assume dose equivalence with other methylphenidate products. Jornay PM's unique pharmacokinetic profile requires independent dose titration 1.